3billion to Participate in ACMG 2025 in Los Angeles

Unveiling AI-powered variant interpretation software ‘GEBRA’ for the first time—Paving the way for advancements in rare disease diagnosis

• First public demonstration and commercialization of AI-powered variant interpretation software ‘GEBRA’ at ACMG 2025, the world’s leading clinical genetics conference
• Enhanced diagnostic accuracy powered by 3billion’s proprietary rare disease data and AI technology
• Following beta testing and improvements, the official launch aims to solve diagnostic challenges for laboratories and hospitals

3billion, a South Korea-based rare disease genetic testing company, will unveil its AI-powered variant interpretation software, ‘GEBRA’, for the first time at the 2025 ACMG Annual Meeting, held from March 18 to 22 in Los Angeles, USA.

ACMG is the most prestigious conference in clinical genetics, and this announcement marks a key moment for 3billion to showcase its expertise in data-driven rare disease diagnostics on a global stage.

Going beyond genetic testing services, 3billion has been advancing AI-driven genome interpretation based on its extensive rare disease dataset. The newly introduced GEBRA has undergone continuous improvements during its beta phase and is now launching as a commercial version aimed at improving diagnostic accuracy and supporting laboratories and hospitals struggling with complex cases.

Dr. Haein Lee of 3billion stated, “We are honored to present our vast rare disease dataset and technology at ACMG 2025. Our goal is to go beyond genetic testing and leverage AI-powered software to support more rare disease patients worldwide.”

Through this participation, 3billion aims to enhance the reliability of rare disease diagnostics and strengthen its position in the global market.

The 2025 ACMG Annual Meeting will take place from March 18 to 22 at the Los Angeles Convention Center, USA.